Industry News
Application of Nivolumab and chemotherapy in the perioperative period of stage III non-small cell lung cancer
Approximately 20% of patients with non-small cell lung cancer (NSCLC) are diagnosed with stage III disease. There is currently no consensus on the most appropriate treatment for these patients.
Nat Rev Drug Discov｜Trends in FDA-approved cancer therapies in the 21st century
On June 21, 2023, Nature Reviews Drug Discovery published an article titled "Trends in the approval of cancer therapies by the FDA in the twenty-first century."
Longitudinal monitoring of circulating tumor DNA in plasma in patients with stage I-IIIA non-small cell lung cancer with EGFR mutations who were cured by surgery
For patients with early-stage epidermal growth factor receptor mutation-positive (EGFR-M+) non-small cell lung cancer (NSCLC), adjuvant chemotherapy after radical surgery is considered the standard of care.
What should I do if the genetic test shows no mutation? Do I need to retest?
Patients who have just been diagnosed with non-small cell lung cancer have raised a common question: "What should I do if the first genetic test shows no mutation? Do I need to retest?" Regarding this issue, I would like to propose the following ideas from the perspective of genetic testing for your reference.
English 
Chinese 
